Lieber mal ´ne XOMA, als vom MediaMarkt die Oma !

fast im Koma!

So eine Sch.... !

Nachkaufen werde ich nicht.
Das Geld dafür lässt sich sicher anderswo besser
einsetzen.
Wenn nochmal in diese Richtung, dann wohl eher in DCGN.
Die steigen seit einigen Tagen wieder. Hoffentlich
haben wir dort das Tief jetzt gesehen.

 

Zwei Meldungen lassen aufhorchen, is ja schön ausgebombt das Teil.

Gruss E.

XOMA Licenses BPI to Zephyr Sciences, Inc.  


BERKELEY, Calif., Nov 10, 2004 (BUSINESS WIRE) -- XOMA Ltd. (NASDAQ: XOMA)
announced today that it has entered into an exclusive worldwide licensing
agreement with Zephyr Sciences, Inc. (Zephyr) for the research, development and
commercialization of products related to its
bactericidal/permeability-increasing protein (BPI), including its NEUPREX(R)
product. The agreement does not cover BPI-derived peptide products. Under the
terms of the agreement, XOMA will be entitled to receive license fees totaling
up to $11 million and milestone payments totaling up to $62 million, as well as
royalties on sales of future products developed and approved under the
agreement. The agreement also includes due diligence provisions related to the
development of BPI in multiple indications, and Zephyr will fund all future
research and development activities. Other financial terms of the license were
not disclosed.

Nov 10, 2004 (M2 PRESSWIRE via COMTEX) -- The Bellwether Report has issued an
aggressive investor alert for shareholders in Xoma Ltd (Nasdaq: XOMA), a
biopharmaceutical company that develops and manufactures products to treat
immunologic and inflammatory disorders, cancer and infectious diseases.

BWR has identified this companies and our analysts will be keeping a close watch
on it over the course of trading as the company came out with a significant
corporate developments yesterday after the Bell.

The company recorded a net loss of $20.1 million or $0.24 per share, compared
with $9.9 million or $0.13 per share for the third quarter of 2003. As of
September 30, 2004, XOMA held $36.4 million in cash, cash equivalents, and
short-term investments, compared with $85.2 million at December 31, 2003.

 

Erste Kaufwelle vorbei...

Sollte in den nächsten sieben Tagen wieder deutlicher anziehen!

  

IT-Angebot trifft IT-Nachfrage: Projektboutique.de

 

bald nix mehr Cash da.

Was dann passiert, zeigen uns die Karstadt-Flaschen
doch gerade !
 

schaun mer mal....
 

kommen musste. Ausgebombte Biotechs sind prima.

Gruss E.  

Da ist doch was im Busch, täglich hohe
Kursverluste.
Habe ein Abstauberlimit im Markt und bin
unschlüssig, ob ich es nicht noch schnell
rausnehmen sollte.
Finde nirgendwo news, die einen derartigen
Kursverfall erklären könnten.
 

Das kann doch nicht endlos so runter gehen, ohne
jegliche technische (Zwischen-)Reaktion !

Habe meinen Abstauber-Kauf erstmal zurückgestellt,
bzw. Limit erheblich verringert.

Die Meldung gestern, dass diversen Managern alle möglichen
Bonis in den Rachen geschmissen werden sollen (trotz
miserablem Kursverlauf) erklärt höchstens den weiteren
Rutsch heute, aber nicht die Verluste der letzten Tage
und Wochen.
 

So eine Scheisse !

Und ich nehme mein Kauflimit raus, mit dem ich
sonst beim letzten Kurs gestern abend bedient
worden wäre. Es darf einfach nicht wahr sein.

Wenn man schon kein Glück hat, dann kommt auch
noch Pech dazu.
 

Xoma shares soar 35% on contract
By Carolyn Pritchard, MarketWatch
Last Update: 7:18 PM ET March 10, 2005  
          §E-mail it | Print | Alert | Reprint | RSS

SAN FRANCISCO (MarketWatch) - Xoma Ltd.'s shares rocketed higher by 35 percent following Thursday's closing bell after the company said it was awarded a $15 million contract from a unit of the National Institutes of Health.

Xoma shares added 37 cents in late trading to change hands for $1.41.

Under terms of the 18-month contract from the National Institute of Allergy and Infectious Diseases, Berkeley, Calif.-based Xoma (XOMA: news, chart, profile) will produce three botulinum neurotoxin monoclonal antibodies designed to protect against the effects of biological agents used in terrorism.

SRI International, an independent, nonprofit research institute based in Menlo Park, Calif. will be a subcontractor under the contract and will develop potency assays to support antibody characterization, Xoma said in a company statement.

 

Wenn ich nicht noch schnell meinen Kaufauftrag
rausnehme.

Was nun, sprach Zeus, und tat - wie immer -
genau das Falsche !
 

 

Hab natürlich das Falsche gemacht !

Kauflimit geändert.
Sonst hätte ich sie jetzt und könnte morgen
30% einsacken.

Na, wenn ich eines Tages gross bin,
ordere ich mal direkt in US.

 

Solche Orders gleichen sich irgendwann wieder aus. Bin schon oft auf den falschen Fuß erwischt worden. Der nächste Trade wird umso besser laufen.

Ich bleibe dabei, aktive Traders werden mehr aus Aktien rausholen als passive.

 

-90% "nur" noch -70% Verlust. Liegenlassen.  

Auch heute kann ich nirgendwo news zum Kursanstieg gestern finden !

?????
 

After Hour / Pre Market USA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Realtime USA

 

 

Xoma 5 Jahre USA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

:-) bin zu einem euro rein !  

 

 

 

May 15, 2009 07:00 AM Eastern Daylight Time
Zymeworks and XOMA to Collaborate on Antibody Research Program
VANCOUVER--(BUSINESS WIRE)--Zymeworks Inc., a privately held computational biotechnology company, today announced it has entered into a research agreement with California-based XOMA Ltd. (Nasdaq: XOMA, www.xoma.com) to optimize an undisclosed antibody using Zymeworks’ ZymeCAD™ suite of predictive protein engineering tools and XOMA’s innovative Targeted Affinity Enhancement™ (TAE™) technology for antibody mutagenesis and optimization. Financial terms are not disclosed.

“XOMA is a recognized leader in the field of antibody optimization and expression, as evidenced by their contributions to the development of marketed antibody therapeutics with Genentech, Inc. (LUCENTIS®) and UCB S.A. (CIMZIA®),” says Ali Tehrani, Ph.D., President and CEO of Zymeworks Inc. “We are excited to collaborate with XOMA on this antibody optimization project. Furthermore, we believe that this collaboration will showcase Zymeworks’ capabilities in protein optimization and engineering for the development of second-generation biologics and therapeutic antibodies.”

“The Zymeworks technology represents a new tool for researchers and developers to optimize the properties of therapeutic proteins,” said Stephen K. Doberstein, Ph.D., XOMA’s Vice President of Research. “We look forward to applying this advanced technology in one of our antibody engineering programs.”

About Zymeworks Inc.

Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop protein therapeutics. Zymeworks’ proprietary ZymeCAD™ molecular simulation platform creates a highly detailed modeling environment that generates novel physical and chemical insights into protein systems. Zymeworks’ protein engineers utilize these new understandings of structure-function relationships to modify proteins to address the needs of strategic partners and to advance Zymeworks’ protein therapeutics pipeline. More information on Zymeworks can be found at http://www.zymeworks.com.

http://www.businesswire.com/portal/site/google/...080&newsLang=en